BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 22936314)

  • 1. Inhibition of bupropion metabolism by selegiline: mechanism-based inactivation of human CYP2B6 and characterization of glutathione and peptide adducts.
    Sridar C; Kenaan C; Hollenberg PF
    Drug Metab Dispos; 2012 Dec; 40(12):2256-66. PubMed ID: 22936314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic activation of mifepristone [RU486; 17beta-hydroxy-11beta-(4-dimethylaminophenyl)-17alpha-(1-propynyl)-estra-4,9-dien-3-one] by mammalian cytochromes P450 and the mechanism-based inactivation of human CYP2B6.
    Lin HL; Zhang H; Hollenberg PF
    J Pharmacol Exp Ther; 2009 Apr; 329(1):26-37. PubMed ID: 19168709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of metabolism dependent inhibition of CYP2B6 mediated bupropion hydroxylation in human liver microsomes by monoamine oxidase inhibitors and prediction of potential as perpetrators of drug interaction.
    Nirogi R; Palacharla RC; Mohammed AR; Manoharan A; Ponnamaneni RK; Bhyrapuneni G
    Chem Biol Interact; 2015 Mar; 230():9-20. PubMed ID: 25656918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6.
    Sridar C; Kent UM; Notley LM; Gillam EM; Hollenberg PF
    J Pharmacol Exp Ther; 2002 Jun; 301(3):945-52. PubMed ID: 12023523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome p450-reductase complex.
    Zhang H; Sridar C; Kenaan C; Amunugama H; Ballou DP; Hollenberg PF
    J Pharmacol Exp Ther; 2011 Sep; 338(3):803-9. PubMed ID: 21659470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of human CYP2B6-catalyzed bupropion hydroxylation by Ginkgo biloba extract: effect of terpene trilactones and flavonols.
    Lau AJ; Chang TK
    Drug Metab Dispos; 2009 Sep; 37(9):1931-7. PubMed ID: 19487249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism-based inactivation of cytochrome P450 2B6 by methadone through destruction of prosthetic heme.
    Amunugama HT; Zhang H; Hollenberg PF
    Drug Metab Dispos; 2012 Sep; 40(9):1765-70. PubMed ID: 22685215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants.
    Hesse LM; Venkatakrishnan K; Court MH; von Moltke LL; Duan SX; Shader RI; Greenblatt DJ
    Drug Metab Dispos; 2000 Oct; 28(10):1176-83. PubMed ID: 10997936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolism of N,N',N"-triethylenethiophosphoramide by CYP2B1 and CYP2B6 results in the inactivation of both isoforms by two distinct mechanisms.
    Harleton E; Webster M; Bumpus NN; Kent UM; Rae JM; Hollenberg PF
    J Pharmacol Exp Ther; 2004 Sep; 310(3):1011-9. PubMed ID: 15121764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thr302 is the site for the covalent modification of human cytochrome P450 2B6 leading to mechanism-based inactivation by tert-butylphenylacetylene.
    Lin HL; Zhang H; Pratt-Hyatt MJ; Hollenberg PF
    Drug Metab Dispos; 2011 Dec; 39(12):2431-9. PubMed ID: 21930824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The grapefruit juice effect is not limited to cytochrome P450 (P450) 3A4: evidence for bergamottin-dependent inactivation, heme destruction, and covalent binding to protein in P450s 2B6 and 3A5.
    Lin HL; Kent UM; Hollenberg PF
    J Pharmacol Exp Ther; 2005 Apr; 313(1):154-64. PubMed ID: 15608076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion.
    Hesse LM; von Moltke LL; Shader RI; Greenblatt DJ
    Drug Metab Dispos; 2001 Feb; 29(2):100-2. PubMed ID: 11159797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism-based inactivation of human cytochrome P450 2B6 by clopidogrel: involvement of both covalent modification of cysteinyl residue 475 and loss of heme.
    Zhang H; Amunugama H; Ney S; Cooper N; Hollenberg PF
    Mol Pharmacol; 2011 Nov; 80(5):839-47. PubMed ID: 21862689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of ritonavir on human CYP2B6 catalytic activity: heme modification contributes to the mechanism-based inactivation of CYP2B6 and CYP3A4 by ritonavir.
    Lin HL; D'Agostino J; Kenaan C; Calinski D; Hollenberg PF
    Drug Metab Dispos; 2013 Oct; 41(10):1813-24. PubMed ID: 23886699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The mechanism-based inactivation of human cytochrome P450 2B6 by phencyclidine.
    Jushchyshyn MI; Kent UM; Hollenberg PF
    Drug Metab Dispos; 2003 Jan; 31(1):46-52. PubMed ID: 12485952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of human CYP2B6 by N,N',N''-triethylenethiophosphoramide is irreversible and mechanism-based.
    Richter T; Schwab M; Eichelbaum M; Zanger UM
    Biochem Pharmacol; 2005 Feb; 69(3):517-24. PubMed ID: 15652242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.
    Xu C; Ogburn ET; Guo Y; Desta Z
    Drug Metab Dispos; 2012 Apr; 40(4):717-25. PubMed ID: 22232427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro.
    Turpeinen M; Nieminen R; Juntunen T; Taavitsainen P; Raunio H; Pelkonen O
    Drug Metab Dispos; 2004 Jun; 32(6):626-31. PubMed ID: 15155554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine.
    Richter T; Mürdter TE; Heinkele G; Pleiss J; Tatzel S; Schwab M; Eichelbaum M; Zanger UM
    J Pharmacol Exp Ther; 2004 Jan; 308(1):189-97. PubMed ID: 14563790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-activity relationship and elucidation of the determinant factor(s) responsible for the mechanism-based inactivation of cytochrome P450 2B6 by substituted phenyl diaziridines.
    Kobayashi Y; Sridar C; Kent UM; Puppali SG; Rimoldi JM; Zhang H; Waskell L; Hollenberg PF
    Drug Metab Dispos; 2006 Dec; 34(12):2102-10. PubMed ID: 16997911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.